Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 13, 2026, 12:35 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 721–744 of 4,291 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Gastro-Intestinal Cancer Clear all

Conditions: Cancer of the Esophagus
Interventions: Panitumumab, Capecitabine, Oxaliplatin, Radiation Therapy (RT); Drug · Radiation
Lead sponsor: Brian Czito; Other
Eligibility: 18 Years to 82 Years
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2012
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Cancer of the Rectum, Neoplasms, Rectal, Rectal Cancer, Rectal Tumors, Rectal Adenocarcinoma
Interventions: Diagnostic Biopsy and Surgical Procedure, Intravoxel incoherent motion MRI (IVIM), Dynamic Contrast Enhanced MRI (DCE-MRI), RNA gene expression analysis; Procedure · Genetic
Lead sponsor: Providence Health & Services; Other
Eligibility: 18 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 2
States / cities: Portland, Oregon

Conditions: Colorectal Cancer
Interventions: Colonoscopy; Procedure
Lead sponsor: US Department of Veterans Affairs; Federal
Eligibility: 50 Years to 75 Years
Enrollment: 3,200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1993 – 2007
U.S. locations: 13
States / cities: Phoenix, Arizona • Tucson, Arizona • Long Beach, California + 10 more

Conditions: Colorectal Cancer, Healthy, no Evidence of Disease
Interventions: counseling intervention, educational intervention; Other
Lead sponsor: Fox Chase Cancer Center; Other
Eligibility: 50 Years and older
Enrollment: 697 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2007
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Head and Neck Cancer, Hearing Loss, Tinnitus, Dysphagia
Interventions: TIMELY REHAB; Other
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years to 89 Years
Enrollment: 74 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2030
U.S. locations: 3
States / cities: Durham, North Carolina • Portland, Oregon • Madison, Wisconsin

Conditions: Colorectal Cancer
Interventions: Capecitabine (Xeloda), Bevacizumab; Drug
Lead sponsor: Translational Oncology Research International; Other
Eligibility: 18 Years and older
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2011
U.S. locations: 12
States / cities: Alhambra, California • Bakersfield, California • Fullerton, California + 9 more

Conditions: Colorectal Cancer, Familial Adenomatous Polyposis
Interventions: Celecoxib, Placebo, eflornithine, Laboratory biomarker analysis, Questionnaire administration; Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 65 Years
Enrollment: 205 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2009
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Time Restricted Eating, Obesity, Weight Loss, Colorectal Cancer
Interventions: Time restricted eating, Calorie Restriction; Behavioral
Lead sponsor: University of Illinois Chicago; Other
Eligibility: 45 Years to 70 Years
Enrollment: 194 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Colorectal Cancer, Breast Cancer, Lung Cancer, Pancreatic Cancer, Colon Cancer
Interventions: AVX701; Biological
Lead sponsor: AlphaVax, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Colorectal Cancer, Early Detection of Cancer
Interventions: Control, Patient activation, Primary care provider activation; Behavioral
Lead sponsor: Ann & Robert H Lurie Children's Hospital of Chicago; Other
Eligibility: 30 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 4
States / cities: New York, New York • University Park, Pennsylvania • Memphis, Tennessee

Conditions: Esophageal Cancer
Interventions: Cisplatin, Irinotecan, Celecoxib, Radiation Therapy, Esophagectomy; Drug · Procedure
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2017
U.S. locations: 2
States / cities: Boston, Massachusetts

Conditions: Breast Cancer, Gastrointestinal Cancer, Hematologic Cancer
Interventions: OPTIMISE; Behavioral
Lead sponsor: Baylor College of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 340 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Esophageal Cancer
Interventions: ArabinoFuranosylGuanine [18F]F-AraG; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Esophageal Cancer
Interventions: Everolimus, LDE 225; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2020
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Inflammatory Bowel Diseases, Colo-rectal Cancer
Interventions: no intervention will be given to patients.; Other
Lead sponsor: University of Texas at Austin; Other
Eligibility: 18 Years to 99 Years
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Stomach Neoplasm
Interventions: Blood Collection, processing and analyses, Gastroscopy and biopsies collection, Urea Breath Test; Procedure · Diagnostic Test
Lead sponsor: National University Hospital, Singapore; Other
Eligibility: 50 Years to 75 Years
Enrollment: 500 participants
Timeline: 2019 – 2033
U.S. locations: 1
States / cities: Stanford, California

Conditions: Gastrointestinal Cancer, Gastric Cancer, Esophageal Cancer, Appendiceal Cancer
Interventions: CYTALUX™ (pafolacianine); Drug
Lead sponsor: Cedars-Sinai Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Esophageal Cancer
Interventions: cisplatin, docetaxel, irinotecan hydrochloride, radiation therapy; Drug · Radiation
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2009
U.S. locations: 1
States / cities: New York, New York

Conditions: Stomach Cancer, Colorectal Cancer, Appendiceal Cancer, Ovarian Cancer, Uterine Cancer, Cervical Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma
Interventions: HIPEC, Mitomycin c, CDDP 50, CDDP 75, Doxorubicin; Device · Drug
Lead sponsor: Holy Name Medical Center, Inc.; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 1
States / cities: Teaneck, New Jersey

Conditions: Cancers With HER2 Expression
Interventions: BAY2701439; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 4
States / cities: Baltimore, Maryland • St Louis, Missouri • New York, New York + 1 more

Conditions: Pain, Cancer, Colonic Diseases
Interventions: GIC-1001; Drug
Lead sponsor: gicare Pharma Inc.; Industry
Eligibility: 40 Years to 70 Years
Enrollment: 308 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 11
States / cities: Scottsdale, Arizona • Anaheim, California • Chula Vista, California + 8 more

Conditions: Colorectal Cancer, Colon Cancer
Interventions: gemcitabine, capecitabine; Drug
Lead sponsor: University of Southern California; Other
Eligibility: 18 Years and older
Enrollment: 53 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2007
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Colorectal Cancer
Interventions: curcumin, rutin, quercetin, sulindac; Dietary Supplement · Drug
Lead sponsor: University of Medicine and Dentistry of New Jersey; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1996 – 2006
U.S. locations: 1
States / cities: New York, New York

Conditions: Colorectal Cancer, Constipation, Impaction, and Bowel Obstruction, Extrahepatic Bile Duct Cancer, Gastric Cancer, Gastrointestinal Stromal Tumor, Nausea and Vomiting, Ovarian Cancer, Pancreatic Cancer, Peritoneal Cavity Cancer, Small Intestine Cancer
Interventions: octreotide acetate; Drug
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2002
U.S. locations: 1
States / cities: Chicago, Illinois

Search by objective public record fields.

Phase I/II Study of Panitumumab, Capecitabine and Oxaliplatin w EBRT for Esophageal Cancer

Immunoscore in Rectal Cancer

Long-term Follow-up Study Designed to Evaluate the Relative Risk of Two Colonoscopy Schedules for Patients With Small Polyps

Genetic Epidemiology Risk Assessment Program or Usual Care in Colorectal Cancer Screening for Healthy Participants

Maximizing Quality of Life After Cancer Through Rehabilitation

Bevacizumab Plus Capecitabine (Xeloda) in Patients With Untreated Metastatic Colorectal Cancer

Celecoxib With or Without Eflornithine in Preventing Colorectal Cancer in Patients With Familial Adenomatous Polyposis

Time-restricted Eating Versus Daily Continuous Calorie Restriction on Body Weight and Colorectal Cancer Risk Markers

A Phase I/II Study With CEA(6D) VRP Vaccine in Patients With Advanced or Metastatic CEA-Expressing Malignancies

ASPIRES (Activating Cancer Survivors and Their Primary Care Providers to Increase Colorectal Cancer Screening) Study

Cisplatin, CPT-11 and Celecoxib With Radiation Therapy and Surgery for Operable Esophageal Cancer

Improving Comprehensive Care of Cancer Patients

18F-AraG PET/CT as a Non-Invasive Imaging Biomarker for Chemoradiation Treatment Response in Esophageal Cancer

LDE225 + Everolimus in Advanced Gastroesophageal Adenocarcinoma

Collection of Gastrointestinal Malignant and Non-malignant Human Samples

Validation of a Molecular Test for Risk-stratification of Patients With High-risk Intestinal Metaplasia (GCEP2 Study)

Intraoperative Imaging of Gastrointestinal Malignancies Using Pafolacianine (CYTALUX™)

Irinotecan, Radiation Therapy, and Docetaxel With or Without Cisplatin in Treating Patients With Locally Advanced Esophageal Cancer

Trial of Cytoreductive Surgery and HIPEC in Patients With Primary and Secondary Peritoneal Cancers

A First in Human Study of BAY2701439 to Look at Safety, How the Body Absorbs, Distributes and Excretes the Drug, and How Well the Drug Works in Participants With Advanced Cancer Expressing the HER2 Protein

A Phase 2a, Proof-of-Concept Study of GIC-1001 in the Management of Visceral Pain During Sedation-Free, Full Colonoscopy

Capecitabine and Gemcitabine in Patients With Metastatic Colorectal Cancer

Sulindac and Plant Compounds in Preventing Colon Cancer

Octreotide as Palliative Therapy for Cancer-Related Bowel Obstruction That Cannot Be Removed by Surgery